Detail akcie TELA Bio Rg online

Business Summary: TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, TELA Bio Inc revenues increased 15% to $59.4M. Net loss increased 4% to $29.8M. Revenues reflect OviTex segment increase of 82% to $62M, OviTex PRS segment increase of 91% to $32.5M. Higher net loss reflects General and administrative - Balancing increase of 5% to $10.1M (expense), Research and development - Balancing va increase of 7% to $6.7M (expense).